Lavoltidine Explained

Lavoltidine (INN,^[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H₂ receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)^[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.^{[3] [4]}

See also

• H₂ receptor antagonist
• Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)

Notes and References

1. WHO Drug Information . 4 . 3 . 1990 . International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30 . World Health Organization. 12 January 2016. 7.
2. Web site: Drug Profile: Lavoltidine. AdisInsight. Springer International Publishing AG. 12 January 2016.
3. Book: Washington N . Antacids and anti-reflux agents . CRC Press . Boca Raton . 1991 . 0-8493-5444-7 .
4. Book: Dictionary of organic compounds . Chapman & Hall . London . 1996 . 0-412-54090-8 .